CA2337771A1 - Anhydrides analogues de cantharidine modifiee utiles pour traiter le cancer - Google Patents

Anhydrides analogues de cantharidine modifiee utiles pour traiter le cancer Download PDF

Info

Publication number
CA2337771A1
CA2337771A1 CA002337771A CA2337771A CA2337771A1 CA 2337771 A1 CA2337771 A1 CA 2337771A1 CA 002337771 A CA002337771 A CA 002337771A CA 2337771 A CA2337771 A CA 2337771A CA 2337771 A1 CA2337771 A1 CA 2337771A1
Authority
CA
Canada
Prior art keywords
cancer
cells
treatment
cantharidin
anhydride modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002337771A
Other languages
English (en)
Inventor
Adam Mccluskey
Jennette A. Sakoff
Stephen Ackland
Alistair T. R. Sim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newcastle Innovation Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2337771A1 publication Critical patent/CA2337771A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention porte sur des anhydrides analogues de cantharidine modifiée utiles pour traiter certaines formes de cancer, et sur des procédés de criblage desdits analogues pour ce qui est de leurs activités anticancéreuses et/ou leur capacité de sensibilisation des cellules cancéreuses à des traitements anticancéreux. Les analogues de la cantharidine modifiée présentent la structure (I) ou (II) dans laquelle R¿1?, R¿2?, R¿3? et R¿4? sont H aryle ou alkyle; X est O, N ou S; Y est OS, NH, NR, R est aryle ou alkyle; A et B sont H ou CH¿3?; W et Z sont CHOH ou C=O. Ces composés inhibent la phosphatase protéique.
CA002337771A 1998-07-14 1999-07-14 Anhydrides analogues de cantharidine modifiee utiles pour traiter le cancer Abandoned CA2337771A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP4665A AUPP466598A0 (en) 1998-07-14 1998-07-14 Product and process
AUPP4665 1998-07-14
PCT/AU1999/000567 WO2000004023A1 (fr) 1998-07-14 1999-07-14 Anhydrides analogues de cantharidine modifiee utiles pour traiter le cancer

Publications (1)

Publication Number Publication Date
CA2337771A1 true CA2337771A1 (fr) 2000-01-27

Family

ID=3808903

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002337771A Abandoned CA2337771A1 (fr) 1998-07-14 1999-07-14 Anhydrides analogues de cantharidine modifiee utiles pour traiter le cancer

Country Status (6)

Country Link
EP (1) EP1104423A4 (fr)
JP (1) JP2002520415A (fr)
KR (1) KR20010074721A (fr)
AU (1) AUPP466598A0 (fr)
CA (1) CA2337771A1 (fr)
WO (1) WO2000004023A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10038043B4 (de) * 2000-08-02 2006-09-07 Walter, Michael, Dr. Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen
AUPR392301A0 (en) * 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
ATE390921T1 (de) * 2001-05-31 2008-04-15 Univ Hong Kong Chinese Zusammensetzung mit demethylcantharidin in kombination mit platinhaltigen antikrebsmitteln und ihre verwendung
BR0314870A (pt) * 2002-10-02 2005-08-02 Aventis Pharma Gmbh Derivados hidroxifenilundecano, processo para sua produção e sua utilização
CN1623993A (zh) * 2003-12-02 2005-06-08 北京键凯科技有限公司 新型的斑蝥胺和去甲斑蝥胺衍生物及其在医药中的应用
CN1304396C (zh) * 2005-04-08 2007-03-14 中山大学 斑蝥素衍生物及其制备方法
EP1967516B1 (fr) 2005-05-18 2009-11-04 Array Biopharma, Inc. Derivés 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide en tant que inhibiteurs MEK pour le traitement de maladies hyperproliferatives
EP1736154A1 (fr) * 2005-06-24 2006-12-27 Friedrich-Alexander-Universität Erlangen-Nürnberg Utilisaton des PP-1 inhibiteurs pour la prévention des cas de missplicing
MX2009008347A (es) * 2007-02-06 2009-10-19 Lixte Biotechnology Holdings I Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
AU2009277086B2 (en) 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (fr) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Procédés de modulation de la régulation cellulaire par inhibition de p53
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
EP2983661B1 (fr) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations d'oxabicycloheptanes et d'oxabicycloheptènes
KR101511857B1 (ko) * 2013-11-01 2015-04-13 주식회사 엘지생활건강 디메틸 칸타리딘을 유효성분으로 포함하는 체모성장 저해용 조성물
CN104447782B (zh) * 2014-12-30 2016-09-14 贵州柏强制药有限公司 溴代去甲斑蝥素单酸苄酯及其合成方法和应用
MD3483164T2 (ro) 2017-03-20 2020-07-31 Forma Therapeutics Inc Compoziții pirolopirolice ca activatori ai piruvat kinazei (PKR)
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (fr) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activation de la pyruvate kinase r
KR20240012182A (ko) 2022-07-20 2024-01-29 고려대학교 산학협력단 칸타리딘을 유효성분으로 포함하는 교모세포종 예방 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954913A (en) * 1975-01-06 1976-05-04 The Standard Oil Company Stabilized nitrile polymers
US4220594A (en) * 1977-11-04 1980-09-02 E. R. Squibb & Sons, Inc. Hexa- and octahydro-4,7-epoxyisobenzofuran-1-ol and hexa- and octahydro-5,8-epoxy-1H-2-benzopyran-3-ol
US4228180A (en) * 1979-11-01 1980-10-14 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs
JPS63170383A (ja) * 1987-02-26 1988-07-14 Nippon Zeon Co Ltd 脂環式ジカルボン酸イミド化合物
DE4134755A1 (de) * 1991-10-22 1993-04-29 Bayer Ag Verwendung von teilweise bekannten substituierten tetrahydrothiophenen als arzneimittel, neue wirkstoffe und verfahren zu ihrer herstellung
DE4134758A1 (de) * 1991-10-22 1993-04-29 Bayer Ag Neue substituierte tetrahydrofurane, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5399725A (en) * 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
WO1995007022A1 (fr) * 1993-09-07 1995-03-16 Zeneca Limited Fongicides
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物

Also Published As

Publication number Publication date
AUPP466598A0 (en) 1998-08-06
JP2002520415A (ja) 2002-07-09
KR20010074721A (ko) 2001-08-09
WO2000004023A1 (fr) 2000-01-27
EP1104423A4 (fr) 2001-10-24
EP1104423A1 (fr) 2001-06-06
WO2000004023A9 (fr) 2000-04-20

Similar Documents

Publication Publication Date Title
US20060030616A1 (en) Anhydride modified cantharidin analogues useful in the treatment of cancer
CA2337771A1 (fr) Anhydrides analogues de cantharidine modifiee utiles pour traiter le cancer
Li et al. Asperversiamides, linearly fused prenylated indole alkaloids from the marine-derived fungus Aspergillus versicolor
JP5926727B2 (ja) 置換イミダゾ［１，２−ｂ］ピリダジン
Shi et al. Design, synthesis and in vitro and in vivo antitumor activities of novel bivalent β-carbolines
Wei et al. Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents
Shi et al. Antitumor agents. 172. Synthesis and biological evaluation of novel deacetamidothiocolchicin-7-ols and ester analogs as antitubulin agents
CN110117271A (zh) 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
JPH08176070A (ja) ジデプシド誘導体及びｐｉ３キナーゼ阻害剤
Bihud et al. Goniolanceolatins A–H, cytotoxic Bis-styryllactones from Goniothalamus lanceolatus
CN110156822B (zh) 一种萘酚-苯硼酸类化合物及其制备方法和用途
EP3160968B1 (fr) Dérivés substitués de chromène en tant qu'inhibiteurs doubles sélectifs des inhibiteurs de la pi3 delta protéine kinase et de la pi3 gamma protéine kinase
Al-Mohammadi et al. Synthesis, in vitro evaluation, and molecular docking studies of benzofuran based hydrazone a new inhibitors of urease
Wang et al. Meroterpenoids with a large conjugated system from Ganoderma lucidum and their inhibitory activities against renal fibrosis
Shults et al. Synthesis and HIV-1 integrase inhibitory activity of spiroundecane (ene) derivatives
NO326464B1 (no) Analoger av camptotecin, anvendelse derav, samt medikament
Liu et al. Retracted Article: Synthesis of xanthone derivatives and anti-hepatocellular carcinoma potency evaluation: induced apoptosis
CN100596298C (zh) 4-脱氧异鬼臼毒素衍生物及其制备方法和医药用途
AU772501B2 (en) Anhydride modified cantharidin analogues useful in the treatment of cancer
CN115124531A (zh) 一类4-氮杂色胺酮芳香硫醚衍生物、制备方法及应用
US20140249312A1 (en) [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer
Dai et al. Synthesis and antitumor effect of sophoridine derivatives bearing an acyclic aryloxy phosphoramidate mustard functionality
AU2004203476A1 (en) Anhydride modified cantharidin analogues useful in the treatment of cancer
CN108358947B (zh) 一种笼状呫吨酮类化合物及其制备方法和用途
Yang et al. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued